A5088251132- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Potassium and Related Disorders
- Statistical Methods in Clinical Trials
- Advanced Causal Inference Techniques
- Neuroendocrine Tumor Research Advances
- Frailty in Older Adults
- Peptidase Inhibition and Analysis
- Cardiovascular Function and Risk Factors
- Breast Cancer Treatment Studies
- Diabetes and associated disorders
- Cancer survivorship and care
- Pancreatic function and diabetes
- Retinal Diseases and Treatments
- Cancer Treatment and Pharmacology
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Hormonal Regulation and Hypertension
- Cancer Risks and Factors
- Pharmacology and Obesity Treatment
- Influenza Virus Research Studies
- Space Science and Extraterrestrial Life
- Gastric Cancer Management and Outcomes
- Chronic Kidney Disease and Diabetes
Brigham and Women's Hospital
2021-2024
Harvard University
2021-2024
Massachusetts General Hospital
2024
University of North Carolina at Chapel Hill
2016-2021
Public Health Department
2016-2019
Centers for Medicare and Medicaid Services
2019
Case Western Reserve University
2012-2017
Background: Both sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) established disease (CVD). Objective: To evaluate whether SGLT2 GLP-1 RAs are associated differential benefit among T2D without CVD. Design: Population-based cohort study. Setting: Medicare U.S. commercial claims data sets (April 2013 to December 2017). Participants:...
No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients a broad spectrum cardiovascular risk. We reported final-year results EMPRISE study, monitoring program designed to evaluate across patient subgroups.
Limited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum cardiorenal risk.To evaluate association cardiovascular outcomes relative to liraglutide and sitagliptin, stratified by age, sex, baseline atherosclerotic disease (ASCVD), heart failure (HF), chronic kidney (CKD).This retrospective cohort study used deidentified Medicare...
Background Randomized trials demonstrate the cardioprotective effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA). We evaluated their relative cardiovascular effectiveness in routine care populations with a broad spectrum atherosclerotic diseases (CVDs) or heart failure (HF). Methods Results identified Medicare beneficiaries from 2013 to 2017, aged >65 years, initiating SGLT2i (n=24 747) GLP‐1RA (n=22 596) after 1‐year...
Epidural analgesia may increase survival after cancer surgery by reducing recurrence. This population-based study compared and treated recurrence gastric resection between patients receiving epidurals those who did not.We used the linked federal Surveillance, Epidemiology, End Results Program/Medicare database to identify aged 66 years or older with nonmetastatic carcinoma diagnosed 1996 2005 underwent resection. Exclusions included diagnosis at autopsy, no Medicare Part B, familial...
Background: Biologic evidence suggests that angiotensin II may play a role in tumor progression or growth. We compared the short-term colorectal cancer (CRC) risk among initiators of angiotensin-converting enzyme inhibitors (ACEI) receptor blockers (ARB) versus guideline-recommended clinical alternatives (beta blockers, calcium channel [CCB], and thiazides). Methods: conducted new-user cohort study on U.S. Medicare beneficiaries aged over 65 years, who initiated antihypertensive monotherapy...
Severe hypoglycemia is associated with adverse clinical outcomes. We evaluated the risk of severe in older adults initiating newer glucose-lowering medications overall and across strata known indicators high risk.
As an organized screening program, the national Breast and Cervical Cancer Early Detection Program (BCCEDP) was launched in early 1990s to improve breast cancer outcomes among underserved women. To analyze impact of BCCEDP on Ohio, this study compared stages mortality across participants, Medicaid beneficiaries, "all others."This linked data Ohio Incidence Surveillance System, Medicaid, database, death certificates, US Census identified 26,426 women aged 40 64 years who had been diagnosed...
Abstract Precisely and efficiently identifying subgroups with heterogeneous treatment effects (HTEs) in real-world evidence studies remains a challenge. Based on the causal forest (CF) method, we developed an iterative CF (iCF) algorithm to identify HTEs defined by important variables. Our method iteratively grows different depths of effect modifiers, performs plurality votes obtain decision trees (subgroup decisions) for family CFs depths, then finds cross-validated subgroup that best...
We compared health care resource utilization (HCRU) and costs for inpatient outpatient services dispensed medications in older adults with type 2 diabetes initiating empagliflozin versus dipeptidyl peptidase 4 inhibitors (DPP-4is).
Abstract Purpose For observational cohort studies that employ matching by propensity scores ( PS ), preliminary stratification consequential predictors of outcome better emulates stratified randomization and potentially reduces variance bias through relaxed dependence on modeling assumptions. We assessed the impact pre‐stratification in two real‐life examples. both, prior evidence from placebo‐controlled randomized clinical trials (RCTs) suggested small or no risk reduction, but analysis...
Observational studies of oseltamivir use and influenza complications could suffer from residual confounding. Using negative control risk periods a outcome, we examined confounding in health-insurance-claims-based study (pneumonia, all-cause hospitalization, dispensing an antibiotic). Within the Food Drug Administration's Sentinel System, identified individuals aged ≥18 years who initiated on diagnosis date versus those did not, during 3 seasons (2014-2017). We evaluated primary outcomes...
Introduction: Diabetic retinopathy (DR) affects one third of adults with diabetes. It is the leading cause blindness among working age and projected to affect 16 million people diabetes in US by 2050. Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT-2i), has demonstrated many cardiovascular renal benefits for patients type 2 (T2D) large outcome trials. However, role empagliflozin other SGLT-2is respect DR not completely understood. We sought assess risk non-proliferative...
Introduction: Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular disease, heart failure, and mortality. We reported the final year results EMPRISE study program in patients type 2 diabetes (T2D) advanced CKD. Here, we aimed to assess effectiveness empagliflozin compared glucagon-like peptide-1 receptor agonists (GLP-1RA) T2D CKD stages 3-4.
Introduction: Hyperuricemia is frequently observed in patients with type 2 diabetes (T2D) and associated increased risk of gout. Empagliflozin lowers serum urate levels by enhancing its urinary excretion. We aimed to compare initiators empagliflozin vs. dipeptidyl peptidase 4 inhibitor (DPP4i) (cohort 1) glucagon like peptide 1 receptor agonist (GLP 1RA) 2) respect the incident gout events.
<p dir="ltr"><b>Objective:</b> We compared healthcare resource utilization (HCRU) and costs for inpatient outpatient services dispensed medications in older adults with type 2 diabetes initiating empagliflozin vs. dipeptidyl peptidase-4 inhibitor (DPP-4i).</p><p dir="ltr"><b>Research Design Methods:</b> The study population included US Medicare fee-for-service beneficiaries (≥65 years) or DPP-4i (08/2014-09/2018)<b>. </b>We estimated rate...
<p dir="ltr"><b>Objective:</b> We compared healthcare resource utilization (HCRU) and costs for inpatient outpatient services dispensed medications in older adults with type 2 diabetes initiating empagliflozin vs. dipeptidyl peptidase-4 inhibitor (DPP-4i).</p><p dir="ltr"><b>Research Design Methods:</b> The study population included US Medicare fee-for-service beneficiaries (≥65 years) or DPP-4i (08/2014-09/2018)<b>. </b>We estimated rate...